Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertension

The Journal of Pharmacology and Experimental Therapeutics
John T LilesLuiz Belardinelli

Abstract

Pulmonary arterial hypertension (PAH) is a progressive disease that often results in right ventricular (RV) failure and death. During disease progression, structural and electrical remodeling of the right ventricle impairs pump function, creates proarrhythmic substrates, and triggers for arrhythmias. Notably, RV failure and lethal arrhythmias are major contributors to cardiac death in patients with PAH that are not directly addressed by currently available therapies. Ranolazine (RAN) is an antianginal, anti-ischemic drug that has cardioprotective effects in experimental and clinical settings of left-sided heart dysfunction. RAN also has antiarrhythmic effects due to inhibition of the late sodium current in cardiomyocytes. We therefore hypothesized that RAN could reduce the maladaptive structural and electrical remodeling of the right ventricle and could prevent triggered ventricular arrhythmias in the monocrotaline rat model of PAH. Indeed, in both in vivo and ex vivo experimental settings, chronic RAN treatment reduced electrical heterogeneity (right ventricular-left ventricular action potential duration dispersion), shortened heart-rate corrected QT intervals in the right ventricle, and normalized RV dysfunction. Chronic RAN ...Continue Reading

References

May 7, 2002·American Journal of Respiratory and Critical Care Medicine·Marius M HoeperLewis J Rubin
May 9, 2008·Journal of Molecular and Cellular Cardiology·Sharon L HaleRobert A Kloner
Sep 30, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Sharad RastogiHani N Sabbah
Nov 10, 2009·The European Respiratory Journal·B SztrymfM Humbert
Mar 26, 2010·Pharmacotherapy·Teena AbrahamEric Balmir
Mar 15, 2011·American Journal of Physiology. Heart and Circulatory Physiology·David BenoistEd White
Jun 3, 2011·Journal of Cardiovascular Pharmacology·Gong ZhaoLuiz Belardinelli
Aug 30, 2011·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Yong-Hu FangStephen L Archer
Dec 3, 2011·Journal of the American College of Cardiology·Mariëlle C van de VeerdonkAnton Vonk-Noordegraaf
Mar 20, 2012·American Journal of Physiology. Heart and Circulatory Physiology·David BenoistEd White
Mar 31, 2012·International Journal of Cardiology·Jonathan D RichStephen L Archer
Jun 26, 2012·International Journal of Cardiology·Karen M OlssonMarius M Hoeper
Jun 30, 2012·The European Respiratory Journal·Norbert F VoelkelMark R Nicolls
Sep 27, 2012·Progress in Cardiovascular Diseases·Archana RajdevAngelo Biviano
Jan 19, 2013·Therapeutic Advances in Respiratory Disease·Véronique Freund-MichelBernard Muller
Feb 1, 2013·Expert Review of Respiratory Medicine·Simon MalenfantSteeve Provencher
Feb 13, 2013·Nature Reviews. Cardiology·Marc A Simon
Apr 11, 2013·Journal of Molecular and Cellular Cardiology·Karl ToischerSamuel Sossalla
Apr 23, 2013·American Journal of Respiratory Cell and Molecular Biology·Yoshihiro TanakaMasayuki Ishihara
Jun 12, 2013·Cardiovascular Research·John C ShryockLuiz Belardinelli
Jul 3, 2013·The Journal of Pharmacology and Experimental Therapeutics·Giorgio Minotti
Jul 23, 2013·American Journal of Physiology. Heart and Circulatory Physiology·Gary L AistrupJ Andrew Wasserstrom
Sep 17, 2013·Seminars in Respiratory and Critical Care Medicine·Julien GuihaireElie Fadel
Sep 27, 2013·International Journal of Cardiology·Marinus A BorgdorffRolf M F Berger
Dec 21, 2013·Journal of the American College of Cardiology·Anton Vonk-NoordegraafPaul M Hassoun
Dec 21, 2013·Journal of the American College of Cardiology·Vallerie V McLaughlinOlivier Sitbon
Apr 17, 2014·Handbook of Experimental Pharmacology·Charles AntzelevitchLuiz Belardinelli

❮ Previous
Next ❯

Citations

Oct 21, 2015·Expert Opinion on Investigational Drugs·Mayank SardanaHarrison W Farber
Nov 8, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Christos G MihosOrlando Santana
Sep 1, 2016·International Journal of Cardiology·Mengqi GongTong Liu
Nov 14, 2016·International Journal of Cardiology·Kinjal BanerjeeAnjan Gupta
Apr 7, 2018·Current Heart Failure Reports·Weiqin LinW H Wilson Tang
May 23, 2020·Biomedizinische Technik. Biomedical Engineering·Hüseyin YanıkSerkan Gürgül
Jul 13, 2020·Clinical and Experimental Pharmacology & Physiology·Oleg Lookin
Apr 17, 2018·Journal of Arrhythmia·George BazoukisCostas Tsioufis
Dec 29, 2018·Journal of the American Heart Association·Kurt W PrinsStephen L Archer
Sep 15, 2017·American Journal of Respiratory and Critical Care Medicine·Grant R BudasRalph T Schermuly
Dec 8, 2020·Pulmonary Circulation·Mark ToshnerKurt W Prins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.